The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0
|
作者：
Szpechcinski, A. [1 ]
Bryl, M. [2 ]
Wojda, E. [1 ]
Czyzewicz, G. [3 ]
Swiniuch, D. [4 ]
Szwiec, M. [5 ]
Ramlau, R. [4 ]
Sliwinski, P. [1 ]
Barinow-Wojewodzki, A. [2 ]
Chorostowska-Wynimko, J. [1 ]
机构：
[1] Inst TB & Lung Dis, Warsaw, Poland
[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland
[3] John Paul II Specialist Hosp, Krakow, Poland
[4] Med Univ Poznan, Poznan, Poland
[5] Univ Hosp Zielona Gora, Zielona Gora, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; EGFR mutations; liquid biopsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [1] Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First-Line EGFR-TKIs
    Su, C.
    Jiang, T.
    Zhao, J.
    Li, X.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S409 - S410
  • [2] Dynamic monitoring and predictive value of circulating tumor cells in EGFR mutant advanced NSCLC patients treated with first-line EGFR-TKIs.
    Su, ChunXia
    Jiang, Tao
    Zhao, Jing
    Zhao, Chao
    Li, Xuefei
    Shen, Jiqiao
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
    Zhang, Chengjuan
    Wei, Bing
    Li, Peng
    Yang, Ke
    Wang, Zhizhong
    Ma, Jie
    Guo, Yongjun
    PLOS ONE, 2017, 12 (03):
  • [4] EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
    Liu, Sangtian
    He, Yayi
    Jiang, Tao
    Ren, Shengxiang
    Zhou, Fei
    Zhao, Chao
    Li, Xuefei
    Zhang, Jie
    Su, Chunxia
    Chen, Xiaoxia
    Cai, Weijing
    Gao, Guanghui
    Li, Wei
    Wu, Fengying
    Li, Jiayu
    Zhao, Jing
    Hu, Qiong
    Zhao, Mingchuan
    Zhou, Caicun
    Hirsch, Fred R.
    LUNG CANCER, 2018, 120 : 82 - 87
  • [5] EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
    Liu, Ao
    Wang, Xiaoming
    Wang, Lian
    Zhuang, Han
    Xiong, Liubo
    Gan, Xiao
    Wang, Qian
    Tao, Guanyu
    BMC CANCER, 2024, 24 (01)
  • [6] Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
    Xiao Liang
    Wei Zhang
    Jun Li
    Jing Zhu
    Jun Shao
    Jing Wang
    Hongshuai Wu
    Jiali Dai
    Jun Li
    Jiali Xu
    Wei Wang
    Renhua Guo
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1211 - 1220
  • [7] Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
    Liang, Xiao
    Zhang, Wei
    Li, Jun
    Zhu, Jing
    Shao, Jun
    Wang, Jing
    Wu, Hongshuai
    Dai, Jiali
    Xu, Jiali
    Wang, Wei
    Guo, Renhua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1211 - 1220
  • [8] Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
    Chen, Hsu-Yuan
    Chen, Chia-Hung
    Liao, Wei-Chih
    Lin, Yu-Chao
    Chen, Hung-Jen
    Hsia, Te-Chun
    Cheng, Wen-Chien
    Tu, Chih-Yen
    BMC PULMONARY MEDICINE, 2024, 24 (01):
  • [9] Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients
    Mohorcic, Katja
    Kern, Izidor
    Janzic, Urska
    Hitij, Nina Turnsek
    Rot, Mitja
    Cufer, Tanja
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S388 - S389
  • [10] Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
    OuYang, Pu-Yun
    Su, Zhen
    Mao, Yan-Ping
    Deng, Wuguo
    Xie, Fang-Yun
    PLOS ONE, 2013, 8 (11):
12345